Evidence map›Paper›PMID 27670823›Full record

ReviewJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2016

The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation.

Harvey Pass, Dorothy Giroux, Catherine Kennedy, Enrico Ruffini, Ayten K Cangir, David Rice, Hisao Asamura, David Waller, John Edwards, Walter Weder and 5 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Implementing CT tumor volume and CT pleural thickness into future staging systems for malignant pleural mesothelioma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2021
    Article
  20. DNA Methylation ofCancers · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Harvey PassDepartment of Cardiothoracic Surgery, New York University Langone Medical Center, New York, New York. Electronic address: harvey.pass@nyumc.org.
Dorothy GirouxCancer Research And Biostatistics, Seattle, Washington.
Catherine KennedyUniversity of Sydney, Putney, New South Wales, Australia.
Enrico RuffiniThoracic Surgery, University of Turin, Chieri, Italy.
Ayten K CangirDepartment of Thoracic Surgery, Ankara University Faculty of Medicine, Ankara, Turkey.
David RiceDepartment of Thoracic Surgery, M. D. Anderson Cancer Center, Houston, Texas.
Hisao AsamuraNational Cancer Center, Keio University School of Medicine, Tokyo, Japan.
David WallerGlenfield Hospital, Groby Road, Leicestershire, United Kingdom.
John EdwardsSheffield Teaching Hospital, Department of Cardiothoracic Surgery, Sheffield, United Kingdom.
Walter WederDivision of Thoracic Surgery, University Hospital, Zurich, Switzerland.
Hans HoffmannThoraxklinik, University of Heidelberg, Heidelberg, Germany.
Jan P van MeerbeeckDepartment of Thoracic Oncology, Antwerp University Hospital, Edegem, Belgium.
Anna NowakUniversity of Western Australia, Subiaco, Western Australia, Australia.
Valerie W RuschThoracic Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For nearly 40 years, there was no generally accepted staging system for malignant pleural mesothelioma. In 1994, members of the International Mesothelioma Interest Group, in collaboration with the International Association for the Study of Lung Cancer, proposed a TNM staging system based on analyses of outcomes in retrospective surgical series and small clinical trials. Subsequently accepted by the American Joint Commission on Cancer and the Union for International Cancer Control for the sixth editions of their staging manuals, this system has since been the international staging standard. However, it has significant limitations, particularly with respect to clinical staging and to the categories for lymph node staging. Here we provide an overview of the development of the International Association for the Study of Lung Cancer malignant pleural mesothelioma staging database, which was designed to address these limitations through the development of a large international data set. Analyses of this database, described in papers linked to this overview, are being used to inform revisions in the eighth editions of the American Joint Commission on Cancer and Union for International Cancer Control staging systems.

Indexed as

Neoplasm StagingHumansLung NeoplasmsMesotheliomaMesothelioma, MalignantPleural NeoplasmsRare DiseasesRegistriesMesotheliomaRegistryStagingTNM

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.